What is HC Wainwright's Estimate for FHTX Q3 Earnings?

Key Points

• HC Wainwright has raised Foghorn Therapeutics' Q3 2025 earnings estimate to ($0.28) per share, signaling a positive shift from their previous estimate of ($0.33).
• The company reported last quarter earnings of ($0.28) EPS, surpassing the consensus estimate by $0.03, despite revenues of $7.56 million falling slightly short of expectations.
• Institutional investors own 61.55% of Foghorn Therapeutics' shares, with Bank of America Corp DE and D.E. Shaw & Co. Inc. significantly increasing their holdings in the company over the last quarter.

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Foghorn Therapeutics in a research report issued on Wednesday, August 6th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.28) per share for the quarter, up from their prior forecast of ($0.33). HC Wainwright currently has a "Strong-Buy" rating on the stock. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Foghorn Therapeutics' Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at ($0.05) EPS.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.03. The firm had revenue of $7.56 million during the quarter, compared to analysts' expectations of $7.62 million.

A number of other research analysts have also recently commented on the company. Citigroup began coverage on Foghorn Therapeutics in a research note on Wednesday, April 23rd. They set an "outperform" rating on the stock. Citizens Jmp assumed coverage on Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $9.00 target price on the stock. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $9.00 target price on shares of Foghorn Therapeutics in a research report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $12.00.

Foghorn Therapeutics Stock Performance

Shares of FHTX traded down $0.02 during trading hours on Friday, hitting $4.70. The stock had a trading volume of 55,750 shares, compared to its average volume of 130,759. The firm has a market cap of $265.41 million, a P/E ratio of -3.94 and a beta of 3.05. The company's fifty day simple moving average is $5.14 and its 200 day simple moving average is $4.59. Foghorn Therapeutics has a 12-month low of $2.94 and a 12-month high of $10.25.

Hedge Funds Weigh In On Foghorn Therapeutics

A number of hedge funds have recently bought and sold shares of FHTX. Bank of America Corp DE boosted its stake in Foghorn Therapeutics by 14.5% in the fourth quarter. Bank of America Corp DE now owns 31,662 shares of the company's stock valued at $149,000 after acquiring an additional 4,002 shares during the period. D. E. Shaw & Co. Inc. boosted its stake in Foghorn Therapeutics by 44.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 100,367 shares of the company's stock valued at $474,000 after acquiring an additional 30,671 shares during the period. BNP Paribas Financial Markets acquired a new position in Foghorn Therapeutics in the fourth quarter valued at approximately $61,000. Lazard Asset Management LLC acquired a new position in Foghorn Therapeutics in the fourth quarter valued at approximately $49,000. Finally, Geode Capital Management LLC boosted its stake in Foghorn Therapeutics by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 682,863 shares of the company's stock valued at $3,224,000 after acquiring an additional 5,477 shares during the period. 61.55% of the stock is currently owned by institutional investors and hedge funds.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.